Clinical trials: Coagulation Defect, open to volunteers
Thrombotic Thrombocytopenic Purpura (TTP)
A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program
Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare blood disorder that some people are born with. It is caused by inherited changes in the ADAMTS13 gene that reduce the body's ability to produce the ADAMTS13 enzyme.
- Trial name
- NCT07429942
- Testing
- No Intervention
- Where
- 8 sites in Germany, Poland
- Volunteers
- 94 people
- Sponsor
- Takeda
Factor X Deficiency
A Database For The Collection Of Clinical, Laboratory, And Treatment Data From Patients With Factor X Deficiency To Define The Natural History Of The Disease And Improve Patient Management
Factor X deficiency is one of the most severe rare bleeding disorders and may lead to serious spontaneous hemorrhages, particularly in patients with severe congenital forms.
- Trial name
- PRO-RBDD-FX (NCT07875478)
- Where
- 2 sites in Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Fondazione Luigi Villa
Myeloproliferative Neoplasm, Essential Thrombocythemia
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
Prospective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.
- Conditions
- Myeloproliferative Neoplasm, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage, Primary Myelofibrosis, Fibrotic Stage
- Trial name
- CALRSUIVI (NCT04942080)
- Testing
- CALR allele burden quantification
- Where
- 10 sites in France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Angers
Immune Thrombocytopenia
TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination
The aim of this study was to observe whether maintaining a high level of platelet count after TPO-RA in patients with primary immune thrombocytopenia (ITP) can induce immune tolerance, develop immune balance in ITP patients, and…
- Trial name
- NCT06478537
- Testing
- Hetrombopag Olamine, Aspirin
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Peking Union Medical College Hospital
Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs)
Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China
The goal of this observational study is to validate the EQ-5D-Y-3L and EQ-5D-Y-5L in measuring health-related quality of life (HRQoL) for paediatric patients with different health conditions in China.
- Conditions
- Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs), Pneumonia Childhood, Neuroblastoma (NB)
- Trial name
- NCT06873672
- Where
- China
- Volunteers
- 360 people
- Sponsor
- RenJi Hospital
Immune Thrombocytopenia
ITP Registry and Accompanying Biospecimen Collection
The objective of this ITP registry is to collect clinical information, including biosampling, from consenting patients with a variety of ITPs at different points in the course of their disease.
- Trial name
- ITP-Registry (NCT05152238)
- Where
- 64 sites in Germany
- Volunteers
- 1,100 people
- Sponsor
- Jena University Hospital
ITP - Immune Thrombocytopenia
Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.
- Trial name
- NCT07093606
- Testing
- Eltrombopag
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Haemophilia B
A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN
This study will collect information on side effects and how well Refixia/REBINYN works during long-term treatment (prophylaxis) in males with haemophilia B.
- Trial name
- NCT03745924
- Testing
- Nonacog beta pegol
- Where
- 30 sites in Austria, Belgium and 11 more
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Oncologic Diseases, Coagulation Defect
Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs
Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)
- Conditions
- Oncologic Diseases, Coagulation Defect, Pain Management
- Trial name
- NCT07384013
- Testing
- metamizole
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rambam Health Care Campus
Von Willebrand Disease (VWD), Acquired Von Willebrand Disease
Endothelial Colony-Forming Cells in Patients With VWD, AVWS and Healthy Subjects
The goal of this observational study is to learn how endothelial colony-forming cells (ECFCs) behave in people with von Willebrand disease (VWD), acquired von Willebrand syndrome (AVWS), and in healthy individuals.
- Trial name
- ECFCs/2022 (NCT07358013)
- Testing
- Blood sample collection for VWF measurements in plasma, Blood sample collection for ECFC isolation and characterization, Genetic testing of VWF
- Where
- Italy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Refractory Immune Cytopenia
BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with refractory ITP associated with autoimmune disease.
- Trial name
- NCT06787989
- Testing
- BCMA-CD19 cCAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Sepsis
Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane
Sepsis remains a global scourge. Before the SARS-CoV-2 pandemic, the World Health Organization estimated approximately 49 million cases annually, resulting in 11 million deaths.
- Trial name
- PLAQSIRIS (NCT06440317)
- Testing
- Hemofiltration membranes (the oXiris membrane® and the HF1400® membrane)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Bordeaux
Von Willebrand Disease (VWD)
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
This is a phase 3 study that will evaluate subcutaneous (SC) VGA039 in patients with von Willebrand Disease (VWD)
- Trial name
- VIVID-6 (NCT07115004)
- Testing
- VGA039
- Where
- 32 sites in United States, Australia and 8 more
- Volunteers
- 60 people
- Sponsor
- Vega Therapeutics, Inc
Thrombotic Thrombocytopenic Purpura (TTP)
Immunological Aspect of Thrombotic Thrombocytopenic Purpura (TTP)
The general objective of the proposed project is to characterise phenotypically and functionally ADAMTS13-specific memory B lymphocytes and autoreactive T lymphocytes, in particular follicular helper T lymphocytes, in the acute…
- Trial name
- Lympho-PTT (NCT06945861)
- Where
- France
- Volunteers
- 44 people
- Sponsor
- University Hospital, Rouen
Peer Bullying Intervention, Vodcast
Early Detection and Kinetics of Sepsis-Induced Coagulopathy in Severe Burn Patients
The purpose of this study is to evaluate the impact of an avatar-supported, teacher-student interactive, vodcast-based peer bullying prevention program-developed for adolescents-on students' ability to identify peer bullying…
- Conditions
- Peer Bullying Intervention, Vodcast, Students
- Trial name
- SIC-BURN-JAAM2 (NCT07905807)
- Testing
- Vodcast-Based Peer Bullying Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Selcuk University
VWD - Von Willebrand's Disease
The Severe Von Willebrand Disease (sVWD) Patient Registry
A web-based registry will be created by the sponsor, VWD Connect Foundation (VCF), to collect data on patients with severe Von Willebrand Disease (sVWD).
- Trial name
- NCT05437536
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- VWD Connect Foundation
Hemophilia
Validity and Reliability of the Figure-of-Eight Walking and Weight-Bearing Lunge Tests in Hemophilia
Recurrent joint bleeding (hemarthrosis) occurs in 70-80% of cases of hemophilia. The three most frequently affected joints are the synovial joints of the ankle, knee, and elbow.
- Trial name
- NCT07851922
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- Yuzuncu Yil University
Immune Thrombocytopenia (ITP), Treatment
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
To evaluate the efficacy and safety of CM336 in the treatment of refractory adult primary immune thrombocytopenia
- Trial name
- NCT06799611
- Testing
- CM336 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Exanguination, Trauma Coagulopathy
Stability of Blood Clotting Products Stored in Emergency Ambulances Under Real-World Conditions
Emergency medical service (EMS) vehicles are exposed to a wide range of environmental conditions, including high temperatures during summer months.
- Trial name
- STABLE-EMS (NCT07646964)
- Where
- Austria
- Volunteers
- 2 people
- Sponsor
- Medical University of Graz
Autoimmune Thrombocytopenia, Warm Autoimmune Haemolytic Anaemia
IASO-782 in Autoimmune Hematological Diseases
This study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with autoimmune hematological diseases.
- Trial name
- NCT06534021
- Testing
- IASO-782 injection
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Shanghai IASO Biotechnology Co., Ltd